SEC Form 4 · accession 0001209191-17-033405
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristen Marie Williams
Officer — CAO and General Counsel
Period of report
May 15, 2017
Accepted (ET)
May 17, 2017 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 15, 2017 | M | 3,125 | $9.25 | A | 18,775 | D | |
| Common Stock | May 15, 2017 | M | 5,937 | $10.52 | A | 24,712 | D | |
| Common Stock | May 15, 2017 | M | 11,979 | $10.81 | A | 36,691 | D | |
| Common StockF2 | May 15, 2017 | S | 21,041 | $50.86 | D | 15,650 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $9.25 | May 15, 2017 | M | 3,125 | D | — | Oct 19, 2021 | Common Stock | 3,125 | 0 | D |
| Stock Option (Right to Buy)F3 | $10.52 | May 15, 2017 | M | 5,937 | D | — | Mar 2, 2022 | Common Stock | 5,937 | 0 | D |
| Stock Option (Right to Buy)F3 | $10.81 | May 15, 2017 | M | 11,979 | D | — | Jun 5, 2022 | Common Stock | 11,979 | 0 | D |
Explanation of responses
- F1The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.75 to $51.00, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.